
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals is a biopharmaceutical company that specializes in drug discovery, early-stage development, and partnerships. With 15 major commercial royalty streams and over 200 active programs, the company has a diverse set of assets in its portfolio. Additionally, its strong free cash flow allows for future royalty acquisitions without relying on external funding. However, there are risks to consider, such as potential declines in key royalty contributors and challenges in integrating acquired companies. Overall, the company's unique market positioning and varied investment approaches make it well-positioned to generate long-term value for shareholders.
Bears say
Ligand Pharmaceuticals is a biopharmaceutical company that relies heavily on partnerships and royalties for revenue. However, the company's recent financial reports have shown declining earnings and lower-than-expected revenues. Additionally, there are concerns about the company's governance standards following its CEO's involvement with a partnership agreement. The success of the company's future hinges on its ability to retain key individuals and make successful capital deployment decisions.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares